171 results on '"Hartry, Ann"'
Search Results
2. Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease
3. Assessing What Matters to People Affected by Alzheimer’s Disease: A Quantitative Analysis
4. Measuring “What Matters Most™” to individuals living with Alzheimer’s disease and care partners: A conceptual model of Alzheimer’s Disease
5. Estimating Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s disease in the United States
6. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment
7. Institutionalization risk and costs associated with agitation in Alzheimer's disease
8. Estimating prevalence of early symptomatic Alzheimer's disease in the United States
9. Health Care Resource Use, Costs, and Diagnosis Patterns in Patients With Schizophrenia and Bipolar Disorder: Real-world Evidence From US Claims Databases
10. The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer's disease
11. Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims Data
12. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder
13. Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes
14. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data
15. Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis
16. A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients
17. Patient preference for early onset of efficacy of preventive migraine treatments
18. Patient Preference for Early Onset of Efficacy in Migraine Prevention (1749)
19. Additional file 1 of Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes
20. Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
21. The importance of care partner input in Alzheimer’s disease (AD) drug development
22. Quantifying what matters most to patients and care partners in Alzheimer's disease
23. Evaluation of what matters most in existing clinical outcomes assessments in Alzheimer's disease
24. Chronic Pain and Pain Medication Use in Chronic Obstructive Pulmonary Disease. A Cross-Sectional Study
25. Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review
26. Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia
27. Additional file 2: of Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis
28. Additional file 1: of Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis
29. Item effects in recognition and fragment completion: contingency relations vary for different subsets of words
30. Commensurability in memory for frequency
31. P4‐673: FINDINGS FROM THE ALZHEIMER'S DISEASE PATIENT AND CAREGIVER ENGAGEMENT (AD PACE) INITIATIVE'S WHAT MATTERS MOST QUALITATIVE STUDY
32. Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder
33. Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course
34. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data
35. Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia
36. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder
37. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder
38. F56. IMPACT OF SIDE EFFECTS DUE TO SECOND-GENERATION ANTIPSYCHOTICS ON THE FUNCTIONING OF PATIENTS WITH SCHIZOPHRENIA: AN OBSERVATIONAL, PATIENT CENTERED, WEB SURVEY
39. S107. HEALTHCARE UTILIZATION AND COST IN SCHIZOPHRENIA AND BIPOLAR DISORDER: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
40. O8.5. SCHIZOPHRENIA AND BIPOLAR DISORDER DIAGNOSIS PATTERNS: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
41. F75. MEDICATION ADHERENCE AND DISCONTINUATION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH ARIPIPRAZOLE ONCE-MONTHLY LONG-ACTING INJECTABLE VERSUS THOSE TREATED WITH ORAL ANTIPSYCHOTICS
42. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder
43. Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications
44. PP029 Hospitalizations And Costs In Bipolar Disorder Patients Initiating Long-acting Injectable Antipsychotics
45. A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting
46. PP040 Hospitalization Costs In Schizophrenia: Long-acting Injectable Antipsychotics Versus Oral Antipsychotic Use
47. VP51 Hospitalizations And Costs In Schizophrenia Patients Initiating Long-acting Injectable Antipsychotics
48. Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics
49. Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia.
50. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.